logo
  

Seagen : FDA Accepts Two SBLA For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer

Seagen Inc. (SGEN) and Astellas Pharma Inc. said that the U.S. Food and Drug Administration has accepted two supplemental biologics license applications for padcev or enfortumab vedotin-ejfv in locally advanced or metastatic urothelial cancer.

The applications were granted Priority Review, with a target action date of August 17, 2021.

The companies noted that the review of both applications will also be conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence.

The first sBLA is based on the phase 3 EV-301 trial and seeks to convert PADCEV's accelerated approval to regular approval.

The second sBLA, based on the pivotal trial EV-201's cohort 2, requests an expansion of the current indication to include patients with locally advanced or metastatic urothelial cancer who have been previously treated with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and are ineligible for cisplatin.

Health authorities in Australia and Canada will evaluate data from EV-301 and EV-201 for initial registrations under Project Orbis.

In March, the companies announced regulatory submissions in Japan and the European Union.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT